Myelodysplastic Syndromes
January 2019 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Myelodysplastic Syndromes abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Myelodysplastic Syndromes. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Myelodysplastic Syndromes. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Myelodysplastic Syndromes every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:De Novo Myelodysplastic Syndrome and Subsequent Diagnosis of Primary Solid Tumors: Evidence from the National Cancer Institute 2001-2011.
Authors:Victoria K, Freedman IG
Institution:University of Vermont Medical Center, Burlington, VT, U.S.A.
Journal:Anticancer Res. 2018 Oct;38(10):5819-5823. doi: 10.21873/anticanres.12922.

2:Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes.
Authors:Stevens BM, Khan N, D'Alessandro A, Nemkov T, Winters A, Jones CL, Zhang W, Pollyea DA, Jordan CT
Institution:Division of Hematology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, 80045, USA. Medicine, Aurora, CO, 80045, USA. Aurora, CO, 80045, USA. Aurora, CO, 80045, USA. Medicine, Aurora, CO, 80045, USA. Medicine, Aurora, CO, 80045, USA.
Journal:Nat Commun. 2018 Sep 12;9(1):3694. doi: 10.1038/s41467-018-05984-x.

3:Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: A systematic review and meta-analysis.
Authors:Gao C, Wang J, Li Y, Zhao H, Li R, Hou L, Zhang Y, Tian S, Liang H, Wang C, Chen X, Wang J
Institution:Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Dongcheng District.; Cross Slope Community Health Service Station, Dongcheng District Community Health Service Management Center, Beijing, China.
Journal:Medicine (Baltimore). 2018 Aug;97(34):e11860. doi: 10.1097/MD.0000000000011860.

4:The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
Authors:Papageorgiou SG, Kontos CK, Kotsianidis I, Vasilatou D, Symeonidis A, Galanopoulos A, Bouchla A, Hatzimichael E, Repousis P, Zikos P, Viniou NA, Poulakidas E, Vassilakopoulos TP, Diamantopoulos P, Diamantopoulos MA, Mparmparousi D, Bouronikou E, Papadaki H, Panayiotidis P, Pappa V
Institution:Second Department of Internal Medicine and Research Unit, University General Hospital 'Attikon', Athens, Greece.; Department of Biochemistry and Molecular Biology, University of Athens, Athens, Greece.; Department of Hematology, Democritus University of Thrace Medical School, University Hospital of Alexandroupolis, Alexandroupolis, Greece.; The Hellenic (Greek) MDS Study Group, Athens, Greece.; General University Hospital of Patras, Patras, Greece.
Journal:Hematol Oncol. 2018 Oct;36(4):693-700. doi: 10.1002/hon.2551. Epub 2018 Sep 7.

5:Autoimmune manifestations associated with myelodysplastic syndromes.
Authors:Grignano E, Jachiet V, Fenaux P, Ades L, Fain O, Mekinian A
Institution:Department of Hematology, Assistance Publique-Hopitaux de Paris, Hopital Cochin, 75014, Paris, France.; Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Assistance Publique - Hopitaux de Paris, Hopital Saint-Antoine, 184, rue du Faubourg Saint-Antoine, 75012, Paris, France. arsene.mekinian@aphp.fr.; UPMC University Paris 06, Paris, France. arsene.mekinian@aphp.fr.; Department of Hematology, Assistance Publique-Hopitaux de Paris, Hopital Saint Louis, 1 avenue Claude Vellefaux, 75010, Paris, France.; Sorbonne Universites, UMPC University Paris 06, INSERM U938, Centre de Recherche Saint-Antoine (CRSA), Paris, France. arsene.mekinian@aphp.fr.
Journal:Ann Hematol. 2018 Nov;97(11):2015-2023. doi: 10.1007/s00277-018-3472-9. Epub 2018 Aug 8.

6:Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy.
Authors:Schuler E, Zadrozny N, Blum S, Schroeder T, Strupp C, Hildebrandt B, Kundgen A, Gattermann N, Aul C, Kondakci M, Kobbe G, Haas R, Germing U
Institution:Department of Hematology, Oncology and Clinical Immunology, University Hospital, Heinrich Heine-University, Moorenstr. 5, 40225, Dusseldorf, Germany. Esther.Schuler@med.uni-duesseldorf.de.; Department of Oncology, University Hospital, Lausanne, Switzerland.; Institute of Human Genetics and Anthropology, Heinrich Heine-University, Duesseldorf, Germany.; Department of Hematology and Oncology, Johannes Hospital Duisburg, Duisburg, Germany.
Journal:Ann Hematol. 2018 Dec;97(12):2325-2332. doi: 10.1007/s00277-018-3466-7. Epub 2018 Aug 4.

7:Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts.
Authors:Baek DW, Lee YJ, Kim H, Ahn SY, Ahn JS, Shin HJ, Lee WS, Lee SM, Song IC, Lee HS, Park SW, Choi Y, Cho YY, Bae SH, Kim HJ, Sohn SK, Moon JH
Institution:Department of Hematology/Oncology, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu, 41944, South Korea. Dongdeok-ro, Jung-gu, Daegu, 41944, South Korea. South Korea. Hwasun, South Korea. Hwasun, South Korea. Hwasun, South Korea. Dongdeok-ro, Jung-gu, Daegu, 41944, South Korea. Dongdeok-ro, Jung-gu, Daegu, 41944, South Korea. jhmoon@knu.ac.kr. jhmoon@knu.ac.kr.
Journal:Ann Hematol. 2018 Dec;97(12):2309-2317. doi: 10.1007/s00277-018-3458-7. Epub 2018 Aug 2.

8:Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition.
Authors:Sharma P, Pollyea DA
Institution:Division of Hematology, University of Colorado School of Medicine, 1665 Aurora Court, Mail Stop F754, Aurora, CO, 80045, USA. daniel.pollyea@ucdenver.edu.
Journal:Curr Hematol Malig Rep. 2018 Aug;13(4):256-264. doi: 10.1007/s11899-018-0464-8.

9:Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.
Authors:Kattamis A, Aydinok Y, Taher A
Institution:First Department of Pediatrics, National and Kapodistrian University of Athens, Athens, Greece. Beirut, Lebanon.
Journal:Eur J Haematol. 2018 Sep;101(3):272-282. doi: 10.1111/ejh.13111. Epub 2018 Jul 27.

10:Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes.
Authors:Gayoso J, Balsalobre P, Kwon M, Herrera P, Bermudez A, Sampol A, Jimenez S, Lopez-Corral L, Serrano D, Pinana JL, Pascual MJ, Heras I, Bento L, Varela R, Humala K, Zabalza A, Laiglesia A, Bastos-Oreiro M, Perez-Corral A, Martinez-Laperche C, Buno I, Diez-Martin JL
Institution:Facultad de Medicina Universidad Complutense, HGU Gregorio Maranon, Madrid, Spain. Spain. Spain. Spain. Spain. Spain. Spain. Spain. Spain.
Journal:Eur J Haematol. 2018 Sep;101(3):332-339. doi: 10.1111/ejh.13103. Epub 2018 Aug 3.

11:Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis.
Authors:Arbab Jafari P, Ayatollahi H, Sadeghi R, Sheikhi M, Asghari A
Institution:a Department of Hematology and Blood Banking, Faculty of Medicine , Mashhad University of Medical Sciences , Mashhad , Iran. University of Medical Sciences , Mashhad , Iran. Medical Sciences , Mashhad , Iran. University of Medical Sciences , Mashhad , Iran. Sciences , Mashhad , Iran.
Journal:Hematology. 2018 Dec;23(10):778-784. doi: 10.1080/10245332.2018.1471794. Epub 2018 May 14.

12:Donor lymphocyte infusion in myeloid disorders.
Authors:Toprak SK
Institution:Ankara University, School of Medicine, Department of Hematology, Cebeci Hospital, Dikimevi, Ankara, Turkey. Electronic address: sktoprak@medicine.ankara.edu.tr.
Journal:Transfus Apher Sci. 2018 Apr;57(2):178-186. doi: 10.1016/j.transci.2018.04.018. Epub 2018 Apr 18.

13:The genetic and molecular pathogenesis of myelodysplastic syndromes.
Authors:Shallis RM, Ahmad R, Zeidan AM
Institution:Division of Hematology/Medical Oncology, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA. School of Medicine, New Haven, CT, USA. School of Medicine, New Haven, CT, USA. University, New Haven, CT, USA.
Journal:Eur J Haematol. 2018 Sep;101(3):260-271. doi: 10.1111/ejh.13092. Epub 2018 Jul 12.

14:Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches.
Authors:Brunner AM, Steensma DP
Institution:Harvard Medical School, and Center for Leukemia at Massachusetts General Hospital, Boston, Massachusetts.
Journal:Clin Adv Hematol Oncol. 2018 Jan;16(1):56-66.

15:Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents.
Authors:Castelli R, Schiavon R, Rossi V, Deliliers GL
Institution:Department of Biomedical and Clinical Sciences Luigi Sacco, Luigi Sacco Hospital Milan, University of Milan, Milan, Italy. roberto.castelli@unimi.it. Milan, University of Milan, Milan, Italy. L. Sacco University Hospital, University of Milan, Milan, Italy.
Journal:Med Oncol. 2018 Apr 19;35(5):76. doi: 10.1007/s12032-018-1135-2.

16:Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
Authors:Arcioni F, Roncadori A, Di Battista V, Tura S, Covezzoli A, Cundari S, Mecucci C
Institution:Department of Medicine, Institute of Hematology and Center for Hemato-Oncology Research (C.R.E.O.), University of Perugia, Perugia, Italy.
Journal:Eur J Haematol. 2018 Jul;101(1):78-85. doi: 10.1111/ejh.13067. Epub 2018 May 22.

17:Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.
Authors:Kantarjian HM, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Carpenter N, Mehta B, Franklin J, Giagounidis A
Institution:Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: hkantarjian@mdanderson.org. Louis, Universite Paris 7, Paris, France. University of Melbourne, Melbourne, Australia. Medizinische Klinik und Poliklinik I, Dresden, Germany. klinische Immunologie, Heinrich-Heine-University of Dusseldorf, Medizinische Klinik und Poliklinik A, Dusseldorf, Germany. Eastern Piedmont, Novara, Italy. Dusseldorf, Germany.
Journal:Lancet Haematol. 2018 Mar;5(3):e117-e126. doi: 10.1016/S2352-3026(18)30016-4. Epub 2018 Jan 26.

18:Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 study.
Authors:Du X, Lai YY, Xiao Z, Liu T, Hu Y, Sun A, Li X, Shen ZX, Jin J, Yu L, Laille E, Dong Q, Songer S, Beach CL
Institution:Department of Hematology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangdong General Hospital affiliated to South China University of Technology, Guangdong, China. Beijing, China. Sciences and Peking Union Medical College, Tianjin, China. China. University of Science and Technology, Wuhan, China. Suzhou, China. College of Medicine, Zhejiang, China.
Journal:Asia Pac J Clin Oncol. 2018 Jun;14(3):270-278. doi: 10.1111/ajco.12835. Epub 2017 Dec 28.

19:Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Authors:Mittelman M, Platzbecker U, Afanasyev B, Grosicki S, Wong RSM, Anagnostopoulos A, Brenner B, Denzlinger C, Rossi G, Nagler A, Garcia-Delgado R, Portella MSO, Zhu Z, Selleslag D
Institution:Tel Aviv Sourasky Medical Center, Sackler Medical Faculty, Tel Aviv University, Tel Aviv, Israel. Electronic address: moshemt@tlvmc.gov.il. Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China.
Journal:Lancet Haematol. 2018 Jan;5(1):e34-e43. doi: 10.1016/S2352-3026(17)30228-4. Epub 2017 Dec 11.

20:Iron overload in myelodysplastic syndromes (MDS).
Authors:Gattermann N
Institution:Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Dusseldorf, Dusseldorf, Germany. gattermann@med.uni-duesseldorf.de.
Journal:Int J Hematol. 2018 Jan;107(1):55-63. doi: 10.1007/s12185-017-2367-1. Epub 2017 Nov 25.

21:Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Authors:Schroeder T, Rautenberg C, Kruger W, Platzbecker U, Bug G, Steinmann J, Klein S, Hopfer O, Nachtkamp K, Kondakci M, Geyh S, Haas R, Germing U, Bornhauser M, Kobbe G
Institution:Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, Moorenstr. 5, 40225, Dusseldorf, Germany. thomas.schroeder@med.uni-duesseldorf.de.; Clinic and Policlinic for Internal Medicine C, Hematology and Oncology, University of Greifswald, Greifswald, Germany.; Medical Clinic and Policlinic I, University Hospital Carl Gustav Carus, Dresden, Germany.; Department of Medicine II, University Hospital Frankfurt, Frankfurt am Main, Germany.; Med. Clinic III, University Medicine Mannheim, Mannheim, Germany.
Journal:Ann Hematol. 2018 Feb;97(2):335-342. doi: 10.1007/s00277-017-3185-5. Epub 2017 Nov 18.

22:Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
Authors:Wong SA, Leitch HA
Institution:Faculty of Medicine, Royal College of Surgeons, Dublin, Ireland. Vancouver, Canada. Electronic address: hleitch@providencehematology.com.
Journal:Leuk Res. 2018 Jan;64:24-29. doi: 10.1016/j.leukres.2017.11.005. Epub 2017 Nov 11.

23:A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
Authors:Navada SC, Fruchtman SM, Odchimar-Reissig R, Demakos EP, Petrone ME, Zbyszewski PS, Holland JF, Silverman LR
Institution:Tisch Cancer Institute, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1079, New York, NY 10029, United States. Electronic address: shyamala.navada@mssm.edu. Electronic address: sfruchtman@onconova.us. at Mount Sinai, One Gustave L. Levy Place, Box 1079, New York, NY 10029, United States. Electronic address: rosalie.odchimar-reissig@mssm.edu. at Mount Sinai, One Gustave L. Levy Place, Box 1079, New York, NY 10029, United States. Electronic address: erin.demakos@mssm.edu. Electronic address: mpetrone@onconova.us. Electronic address: pzbyszewski@onconova.us. at Mount Sinai, One Gustave L. Levy Place, Box 1079, New York, NY 10029, United States. Electronic address: james.holland@mssm.edu. at Mount Sinai, One Gustave L. Levy Place, Box 1079, New York, NY 10029, United States. Electronic address: lewis.silverman@mssm.edu.
Journal:Leuk Res. 2018 Jan;64:10-16. doi: 10.1016/j.leukres.2017.11.006. Epub 2017 Nov 11.

24:Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.
Authors:Schroeder T, Rautenberg C, Haas R, Germing U, Kobbe G
Institution:Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, Moorenstr. 5, 40225, Dusseldorf, Germany. thomas.schroeder@med.uni-duesseldorf.de.
Journal:Int J Hematol. 2018 Feb;107(2):138-150. doi: 10.1007/s12185-017-2364-4. Epub 2017 Nov 15.

25:Coffee and green tea consumption and subsequent risk of acute myeloid leukemia and myelodysplastic syndromes in Japan.
Authors:Ugai T, Matsuo K, Sawada N, Iwasaki M, Yamaji T, Shimazu T, Goto A, Inoue M, Kanda Y, Tsugane S
Institution:Division of Molecular and Clinical Epidemiology, Aichi Cancer Center Research Institute, Nagoya, Japan. Saitama, Japan.
Journal:Int J Cancer. 2018 Mar 15;142(6):1130-1138. doi: 10.1002/ijc.31135. Epub 2017 Nov 21.

26:Epigenetics in myelodysplastic syndromes.
Authors:Heuser M, Yun H, Thol F
Institution:Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany. Electronic address: heuser.michael@mh-hannover.de. Addenbrooke's Hospital, UK; Wellcome Trust-Medical Research Council, Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK. Hannover Medical School, Hannover, Germany.
Journal:Semin Cancer Biol. 2018 Aug;51:170-179. doi: 10.1016/j.semcancer.2017.07.009. Epub 2017 Aug 2.

27:The burden of autoimmunity in myelodysplastic syndromes.
Authors:Fozza C
Institution:Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy.
Journal:Hematol Oncol. 2018 Feb;36(1):15-23. doi: 10.1002/hon.2423. Epub 2017 Apr 27.

For a FREE PREVIEW of the Medifocus Guidebook on Myelodysplastic Syndromes click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Myelodysplastic Syndromes click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Myelodysplastic Syndromes...
at a Special 20% Discount


Medifocus Guidebook on Myelodysplastic Syndromes

Updated: January 4, 2019
189 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Myelodysplastic Syndromes is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

MS43343123

Coupon Expires: March 21, 2019



What Our Customers Are Saying...

"I purchased the MediFocus Guidebook on Myelodysplastic Syndromes to help my father understand the disease that he has. Doctors in France do not communicate very well the various treatment options neither do they tell you about the prognosis with enough clarity and confidence. We live in France and we believe there is no equivalent in Europe to the service you offer. We have read the Guidebook attentively and have learned a great deal about this condition. The wording is simple enough to be understandable even for non-native English speakers. It was money well spent!"
P.M.
Saint Ismier, France


"Your MediFocus Guidebook on Myelodysplastic Syndromes has been a valuable companion in providing wise counsel to a beleaguered soul. Many times I was comforted by knowing that I could have my questions answered correctly and completely by using your Guidebook. I wouldn't be without it for anything. Thank you again and again."
S.M.
Rockville, Maryland


"Your Medifocus Guidebook on Myelodysplastic Syndromes has been extremely valuable to me in understanding the complicated disease that afflicts me. It can be very depressing but to understand it intellectually can be very calming and heartening. Fear of the unknown is most devastating and your Guidebook provides the facts in an understandable way without 'watering-down' the science. Thank you for your outstanding publication."
N.M.
Los Angeles, California



  
Medifocus Digest Alert is published by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2019 Medifocus, Inc. All rights reserved.